Evidence map›Paper›PMID 41064664›Full record

ArticleJCEM case reports2025

Genomic Sequencing in Oncocytic Adrenal Carcinoma May Provide Insights into Disease Progression and Treatment Options.

Hye Jeong Han, Alessandra Moore, Numbereye Numbere, Adrienne Victor, Inga Harbuz-Miller

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hye Jeong HanDepartment of Medicine, Division of Endocrinology & Metabolism, University of Rochester, Rochester, NY 14642, USA.ORCID https://orcid.org/0000-0002-8313-8456
Alessandra MooreDepartment of Surgery, Division of Surgical Oncology, University of Rochester, Rochester, NY 14642, USA.
Numbereye NumbereDepartment of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY 14642, USA.
Adrienne VictorDepartment of Medicine, Division of Hematology & Oncology, University of Rochester, Rochester, NY 14642, USA.ORCID https://orcid.org/0000-0001-7130-7366
Inga Harbuz-MillerDepartment of Medicine, Division of Endocrinology & Metabolism, University of Rochester, Rochester, NY 14642, USA.ORCID https://orcid.org/0000-0002-6254-237X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncocytic adrenal carcinoma (OAC) is a rare histologic subtype of adrenal cortical carcinoma (ACC) characterized by >90% oncocytic cells. Unlike ACC, OACs have a reduced incidence of adrenal hormone production, larger size, and longer time to recurrence (17.5 months vs 8 months). Genetic mutations in

Indexed as

adrenal cortical carcinoma (ACC)CTNNB1 mutationHelsinki scoring systemoncocytic adrenal carcinoma (OAC)

Identifiers

PMID41064664
PMCPMC12501496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.